On September 7, 2022 Acupath Labs and UroGPO reported in April a partnership to make URO17 available to the UroGPO membership nationwide (Press release, Acupath Laboratories, SEP 7, 2022, View Source [SID1234619210]). URO17 is a non-invasive, cost-effective urine-based biomarker used in diagnosis and management of bladder cancer, the 6th most common form of cancer in the US. Available as a Laboratory Developed Test (LDT) in the United States, Acupath was the first lab worldwide to offer URO17 in July 2019 and has performed over 20,000 tests since that time. UroGPO will offer discounted reagents and information for the URO17 test to the members of their Group Purchasing Organization.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Each year over 85,000 new cases of bladder cancer are diagnosed, while many more patients are subjected to unnecessary and invasive procedures to address common symptoms such as hematuria, or blood in the urine. With a high sensitivity and negative predictive value (NPV), URO17 can provide invaluable information and help clinicians better risk stratify patients, identifying those that require additional and often invasive follow up treatments, and those that do not. Further, for urology practices with Physician Office Labs (POL’s) or commercial / hospital pathology labs, URO17 represents an opportunity to generate a significant new and clinically relevant revenue stream.
Acupath Labs and the UroGPO network are excited to formally make URO17 available to urology practices nationwide.
"Acupath has worked closely with UroGPO for the last several years and we are excited to formally make URO17 available to urology practices nationwide through the UroGPO network. In addition to the compelling clinical utility, our clients appreciative how URO17 can be seamlessly integrated into their practices’ workflow and in office pathology labs, often with no additional investment." says John Cucci, Chief Sales Officer of Acupath Laboratories, Inc.
"As we expand our solutions around bladder cancer care, UroGPO has been pleased with the addition of URO17 to our membership offerings. Acupath partners with members as a consultant for all things implementation and optimization, which has proven to be a unique point of value in this offering. This partnership has strengthened our commitment to improving patient outcomes," says Palmer DePetro, Sr. Director, Contracting at Specialty Networks.